Brief: Actinium Pharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock And Warrants
17/04/2019 21:12
April 17 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PUBLIC
OFFERING OF COMMON STOCK AND WARRANTS
* ACTINIUM PHARMACEUTICALS - INTENDS TO USE NET PROCEEDS TO
FUND
ONGOING PIVOTAL, PHASE 3 SIERRA TRIAL FOR ITS LEAD PRODUCT
CANDIDATE IOMAB-B
* ACTINIUM PHARMACEUTICALS - TO USE PROCEEDS TO SUPPORT
ANTIBODY
WARHEAD ENABLING TECHNOLOGY PLATFORM, INCLUDING IOMAB-ACT
PROGRAM
Source text for Eikon: ID:nPn13wVdya
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities